Volume 12, Number 5—May 2006
Human Bocavirus in Children
Highlight and copy the desired format.
|EID||Foulongne V, Rodière M, Segondy M. Human Bocavirus in Children. Emerg Infect Dis. 2006;12(5):862-863. https://dx.doi.org/10.3201/eid1205.051523|
|AMA||Foulongne V, Rodière M, Segondy M. Human Bocavirus in Children. Emerging Infectious Diseases. 2006;12(5):862-863. doi:10.3201/eid1205.051523.|
|APA||Foulongne, V., Rodière, M., & Segondy, M. (2006). Human Bocavirus in Children. Emerging Infectious Diseases, 12(5), 862-863. https://dx.doi.org/10.3201/eid1205.051523.|
To the Editor: Respiratory tract infection is a major cause of illness in children. Despite the availability of sensitive diagnostic methods, detecting infectious agents is difficult in a substantial proportion of respiratory samples from children with respiratory tract disease (1). This fact suggests the existence of currently unknown respiratory pathogens.
A new virus has been recently identified in respiratory samples from children with lower respiratory tract disease in Sweden (2). Analysis of the full-length genome sequence showed that this virus is closely related to bovine parvovirus and canine minute virus and is a member of the genus Bocavirus, subfamily Parvovirinae, family Parvoviridae. This virus has been provisionally named human Bocavirus (HBoV) (2). HBoV in respiratory samples from Australian children was also recently reported (3). Involvement of this new virus in respiratory tract diseases merits further investigation. We have therefore retrospectively tested for HBoV nasopharyngeal samples collected from children <5 years of age hospitalized with respiratory tract disease.
Samples were collected from 262 children from November 1, 2003, to January 31, 2004. The samples were tested for respiratory viruses by using direct immunofluorescence assays with monoclonal antibodies to respiratory syncytial virus; influenza virus types A and B; parainfluenza virus types 1, 2, and 3; and adenovirus. Samples were also placed on MRC5 cell monolayers for virus isolation and tested for human metapneumovirus by reverse transcription–polymerase chain reaction (RT-PCR). Nucleic acids were extracted from samples, stored at –80°C, and tested for HBoV DNA by PCR with primers specific for the predicted NP1 gene as previously described (2). The expected product size was 354 bp. In each experiment, a negative control was included, and positive samples were confirmed by analyzing a second sample. Amplification specificity was verified by sequencing.
Nine (3.4%) samples were positive. Comparison of PCR product sequences of these 9 isolates (GenBank accession nos. AM109958–AM109966) showed minor differences that occurred at 1 to 4 nucleotide positions, and a high level of sequence identity (99%–100%) was observed with the NP1 sequences of the previously identified ST1 and ST2 isolates (2). This finding indicates that HBoV is a highly conserved virus.
HBoV was the only virus identified in 6 children and was associated with respiratory syncytial virus in 3 other children. An infection with other respiratory viruses was detected among 153 (60.5%) of the 253 HBoV-negative children. The viruses identified were respiratory syncytial virus in 114 (43.5%) samples, human metapneumovirus in 27 (10.3%) samples, influenza A virus in 14 (5.4%) samples, rhinovirus in 4 (1.5%) samples, adenovirus in 2 (0.8%) samples, and parainfluenza virus type 3 in 1 (0.4%) sample. Respiratory syncytial virus was associated with human metapneumovirus in 9 (3.4%) samples.
Clinical characteristics of the HBoV-infected children are shown in the Table. Children infected with only HBoV had mild-to-moderate fevers. Leukocyte counts and C-reactive protein levels were normal or moderately elevated. Chest radiographs obtained for 7 children showed abnormalities such as hyperinflation and interstitial infiltrates. Bronchiolitis was the major diagnosis. Dyspnea, respiratory distress, and cough were the most common respiratory symptoms observed. Four (44%) HBoV-infected children were born preterm, which suggests that these children have an increased susceptibility to HBoV-associated diseases. All children recovered and were discharged within 1 to 6 days.
The 3.4% incidence of HBoV observed in our study is similar to that (3.1%) reported by Allander et al. (2). HBoV was the only infectious agent identified in 6 children, which suggests that it was the causative agent of the disease. However, more studies conducted in children with and without respiratory disease as well as in adults and elderly persons are needed to better assess the pathogenic role of HBoV.
This work was supported by a grant from the Programme Hospitalier de Recherche Clinique of the Montpellier University Hospital (AOI 2003).
- Juven T, Mertsola J, Waris M, Leimonen M, Meurman O, Roivanen M, Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr Infect Dis J. 2000;19:293–8.
- Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Anderson B. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci U S A. 2005;102:12891–6.
- Sloots TP, McErlean P, Speicher DJ, Arden K, Nissen MD, Mackay IA. Evidence of human coronavirus HKU1 and human bocavirus in Australian children. J Clin Virol. 2005;35:99–102.
TableCite This Article
Please use the form below to submit correspondence to the authors or contact them at the following address:
Vincent Foulongne, Laboratory of Virology, Montpellier University Hospital, 80 Ave A. Fliche, Montpellier 34295, France
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: January 12, 2012
- Page last updated: January 12, 2012
- Page last reviewed: January 12, 2012
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)